Our Company
Xanamem^® (emestedastat)
Clinical Trials
Investor Centre
News
Contact Us

BACK TO NEWS

admin • 08 May 2019

Edison Investment Research
Phase II XanADu trial results

Enjoyed this read?

Stay up to date with our latest research.

Related articles

Press Releases and Media

Daily pill to treat dementia gets nod

Courier Mail • September 17, 2025

Press Releases and Media

A novel oral treatment for Alzheimer’s: Actinogen’s pivotal trial currently recruiting participants in the US

PR Newswire • July 22, 2025

Press Releases and Media

FIVEAA Adelaide radio interview with Dr Steven Gourlay on once-a-day Alzheimer’s pill [8m 25s]

FIVEAA • July 1, 2025

Our Company
Xanamem^® (emestedastat)

Clinical Trials

Investors
News
Contact Us
Target Market Determination

Copyright © 2025 Actinogen